SynthesisExpert opinion on biological therapy2008
Genetic basis for kidney cancer: opportunity for disease-specific approaches to therapy.
Synthesis in Expert opinion on biological therapy, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 65 citations in OpenAlex.
- Pattern of care and treatment outcomes of metastatic non-clear cell kidney cancer: a single centre experience from India.Ecancermedicalscience · 2024Article
- Systemic Treatment for Advanced and Metastatic Non-Clear Cell Renal Cell Carcinoma: Examining Modern Therapeutic Strategies for a Notoriously Challenging Malignancy.Journal of kidney cancer and VHL · 2023Review
- Construction and Validation of Protein Expression-related Prognostic Models in Clear Cell Renal Cell Carcinoma.Journal of Cancer · 2023Article
- Contemporary treatment of metastatic renal cell carcinoma.Medical oncology (Northwood, London, England) · 2018Review
- The emerging role and targetability of the TCA cycle in cancer metabolism.Protein & cell · 2018Review
- SENP1 promotes proliferation of clear cell renal cell carcinoma through activation of glycolysis.Oncotarget · 2016Article
- Cabozantinib in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience.Therapeutic advances in urology · 2016Review
- Renal Carcinogenesis, Tumor Heterogeneity, and Reactive Oxygen Species: Tactics Evolved.Antioxidants & redox signaling · 2016Review
- Combination of mTOR and MAPK Inhibitors-A Potential Way to Treat Renal Cell Carcinoma.Medical sciences (Basel, Switzerland) · 2016Review
- Unilateral renal oncocytosis and combined hybrid tumor: a case report and review of the literature.Japanese journal of radiology · 2014Review
- Review
- Higher circulating expression levels of miR-221 associated with poor overall survival in renal cell carcinoma patients.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- Epidemiology and staging of renal cell carcinoma.Seminars in interventional radiology · 2014Review
- Proteomic analysis of signaling network regulation in renal cell carcinomas with differential hypoxia-inducible factor-2α expression.PloS one · 2013Article
- TCA Cycle Defects and Cancer: When Metabolism Tunes Redox State.International journal of cell biology · 2012Article
- Long-term outcomes, branch-specific expressivity, and disease-related mortality in von Hippel-Lindau type 2A.Familial cancer · 2011Article
- Germline and somatic DNA methylation and epigenetic regulation of KILLIN in renal cell carcinoma.Genes, chromosomes & cancer · 2011Article
- Impact of genetics on the diagnosis and treatment of renal cancer.Current urology reports · 2011Article
- Familial renal cancer: molecular genetics and surgical management.International journal of surgical oncology · 2011Article
- Tumor biology and prognostic factors in renal cell carcinoma.The oncologist · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
backgroundKidney cancer is not a homogenous entity; it is comprised of many different tumor types, with different biologies and molecular mechanisms leading to disease and therefore different treatment approaches.
objectiveTo describe the genetic basis and biochemical pathways underlying inherited forms of renal cancer, specifically in four described syndromes (von Hippel-Lindau [VHL], hereditary papillary renal cancer [HPRC], Birt-Hogg-Dubé [BHD] and hereditary leiomyomatosis renal cell carcinoma [HLRCC]), and to elucidate how the understanding of these diseases enables the possibility of disease-specific approaches to therapy.
methodsA systematic review of the published literature on inherited and sporadic forms of renal cancer was performed.
conclusionUnderstanding of the biology and mechanisms of different forms of kidney cancer provides an opportunity for development of new treatment options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.